Study guide

Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

Key Takeaways Explain This Topic AI

Systematic reviews follow transparent, pre-specified, reproducible protocols guided by PRISMA guidelines and standardized Cochrane Risk of Bias assessments to reduce and expose selection bias; adherence to reporting guidance does not guarantee sound review conduct.

In meta-analysis, the Forest plot visualizes study-level point estimates and 95% confidence intervals alongside a pooled diamond estimate; fixed-effect models assume a single true underlying effect, whereas random-effects models account for between-study clinical and methodological heterogeneity.

Statistical heterogeneity is evaluated quantitatively via the Cochrane Q Q Q test and the I 2 I^2 I 2 index ( I 2 ≥ 50 % − 75 % I^2 \ge 50\% - 75\% I 2 ≥ 50% − 75% indicating substantial heterogeneity); funnel asymmetry and appropriate tests can suggest small-study effects but do not alone establish publication bias.

Health economic evaluations guide resource prioritization: Cost-Effectiveness Analysis evaluates natural clinical units, while Cost-Utility Analysis measures Quality-Adjusted Life Years (QALYs); for a more-effective, more-costly intervention, its Incremental Cost-Effectiveness Ratio ( I C E R = Δ C / Δ E ICER = \Delta C / \Delta E I CER = Δ C /Δ E ) is compared with the applicable threshold; dominated options are rejected.

Paediatric clinical research ethics, grounded in the Declaration of Helsinki, GCP, and European Clinical Trials Regulation (Regulation EU No 536/2014), require representative informed consent, age-appropriate information and assent-seeking when the child is capable, strict proportionality between risk and burden, and rigorous safeguards for emergency deferred consent in critically ill children.

Last updated: November 2026

Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

Evidence-Based Paediatrics (EBP) integrates individual clinical expertise with the best available external clinical evidence from systematic research. Individual randomised trials are often limited by small sample sizes, single-center designs, and geographic restrictions. Consequently, systematic reviews and meta-analyses occupy the summit of the traditional evidence hierarchy. However, applying synthesized evidence requires the ability to critically dissect Forest plots, detect publication bias, and assess health economic analyses. Furthermore, paediatric research involves uniquely vulnerable subjects, demanding strict adherence to ethical, regulatory, and consent frameworks.

Systematic Reviews versus Narrative Reviews & PRISMA Reporting

Medical reviews fall into two fundamentally distinct categories: traditional narrative reviews and formal systematic reviews.

Feature Narrative Review Systematic Review

Question Focus Broad, general topic overview (e.g., "Management of Paediatric Pneumonia") Narrow, structured question formulated via PICO (Population, Intervention, Comparator, Outcome)

Search Strategy Non-systematic, subjective; search terms and databases rarely specified Comprehensive, explicit, reproducible across multiple databases (MEDLINE, Embase, Cochrane)

Selection Criteria Subjective, idiosyncratic; prone to author cherry-picking and confirmation bias Explicit, predefined, transparent inclusion and exclusion criteria

Critical Appraisal Variable or absent; rarely utilizes standardized quality frameworks Rigorous, formal risk-of-bias appraisal using validated instruments (Cochrane RoB 2, ROBINS-I)

Synthesis Qualitative, narrative summary reflecting author opinions Quantitative meta-analysis (when data permit) or formal narrative synthesis

The PRISMA 2020 Statement

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework provides an evidence-based minimum set of items for reporting reviews. Its flow diagram tracks identification, screening and inclusion, distinguishing records, reports and studies. A simplified example is: [Simplified PRISMA 2020 Flow]

  • Identification: Database/register records identified (n =4250)
  • | Duplicates removed (n =1120)
  • v
  • Screening: Records screened (n =3130); records excluded (n =2980)
  • v
  • Reports sought and retrieved (n =150; none unavailable)
  • Reports assessed (n =150); excluded with reasons (n =126)
  • v
  • Included: Reports (n =24) describing studies (n =24)
  • Studies contributing to meta-analysis (n =18)
  • Assessing Methodological Quality: Cochrane Risk of Bias (RoB 2)

The Cochrane RoB 2 tool evaluates five distinct domains for randomised trials:

Bias arising from the randomisation process (allocation sequence generation and concealment).

Bias due to deviations from intended interventions (blinding of participants and personnel).

Bias due to missing outcome data (their extent, reasons and relation to outcomes; ITT labels alone do not remove this bias).

Bias in measurement of the outcome (blinding of outcome assessors).

Bias in selection of the reported result (selective outcome reporting versus trial registration protocols).

Meta-Analysis: Forest Plots, Models, and Heterogeneity Analytics

Meta-analysis is the mathematical and statistical combination of results from two or more independent clinical studies to generate a single pooled quantitative summary effect estimate.

Dissecting the Forest Plot

The Forest plot is the universal graphical display of a meta-analysis: Illustrative trials DL weight Risk ratio [95% CI] CI crosses RR=1?

  • --------------------------------------------------------------------------
  • Schmidt 22.2% 0.60 [0.42,0.85] No
  • Alvarez 34.1% 0.75 [0.60,0.94] No
  • Dubois 15.1% 0.45 [0.28,0.72] No
  • Kowalski 28.6% 0.82 [0.62,1.08] Yes
  • --------------------------------------------------------------------------
  • Random-effects summary 0.68 [0.55,0.84] No
  • Q=5.71 (df=3, p=0.127); I2=47%; tau2=0.0227

Log-effect SEs estimated as [ln(upper CI)-ln(lower CI)]/3.92.

DL = DerSimonian–Laird; values rounded. In a graphical forest plot,

the Kowalski whisker crosses 1; the summary diamond lies to its left.

Individual Study Lines : Each trial is displayed on a horizontal line. The square marks the study's point estimate; the area of the square is directly proportional to the study's weight in the meta-analysis (inversely related to variance). The horizontal whisker lines represent the 95 % 95\% 95% confidence interval.

Vertical Solid Line (Line of No Effect) : Corresponds to R R = 1.0 RR = 1.0 RR = 1.0 or O R = 1.0 OR = 1.0 OR = 1.0 for ratio metrics (or 0.0 0.0 0.0 for continuous mean difference metrics). If an individual study's confidence interval crosses this line, that study is not statistically significant.

The Summary Diamond : Represents the pooled effect estimate. The horizontal width of the diamond corresponds precisely to the 95 % 95\% 95% confidence interval of the pooled effect, and the vertical center represents the point estimate. If the lateral edges of the diamond do not touch or cross the vertical line of no effect, the pooled summary result is statistically significant .

Fixed-Effect versus Random-Effects Statistical Models

Modeling Parameter Fixed-Effect Model Random-Effects Model

Core Mathematical Assumption Assumes that one true identical effect size underlies every single study; all observed variation between trials is due purely to random within-study sampling error. Assumes that the true effect size varies between studies due to differing patient ages, illness severities, co-morbidities, or drug dosing regimens.

Sources of Variance Accounts only for within-study variance ( σ i 2 \sigma_i^2 σ i 2 ​ ). Accounts for both within-study variance ( σ i 2 \sigma_i^2 σ i 2 ​ ) AND between-study variance ( τ 2 \tau^2 τ 2 , tau-squared).

Study Weighting Heavily dominated by large trials with huge sample sizes; tiny studies receive almost zero weight. Distributes weights more equitably, giving relatively greater weight to smaller studies.

Confidence Intervals Common-effect precision ignores between-study variance. Usually wider with estimated heterogeneity; not automatically more conservative or unbiased.

Clinical Application Estimates a common effect when that assumption is defensible; do not choose solely from an I 2 I^2 I 2 cutoff. Estimates an average of varying effects when studies can meaningfully be combined; it does not resolve clinical incompatibility.

Quantifying and Investigating Heterogeneity

Heterogeneity refers to variability among studies in clinical populations, intervention protocols, or statistical results.

Cochrane's Q Q Q Test : A Chi-square test evaluating whether the observed variation between study effect sizes exceeds what would be expected by chance alone ( d f = k − 1 df = k - 1 df = k − 1 , where k k k is the number of studies). Because the Q Q Q test has low statistical power when the number of studies is small, a more permissive significance threshold of p < 0.10 p < 0.10 p < 0.10 is conventionally used.

Higgins I 2 I^2 I 2 Statistic : Quantifies the percentage of total variation across studies that is attributable to true heterogeneity rather than random chance: I 2 = max ⁡ ( 0 , Q − d f Q ) × 100 % I^2 = \max\left(0, \frac{Q - df}{Q}\right) \times 100\% I 2 = max ( 0 , Q Q − df ​ ) × 100% Use I 2 = 0 I^2=0 I 2 = 0 when Q = 0 Q=0 Q = 0 ; negative estimates are set to zero.

I 2 = 0 % − 25 % I^2 = 0\% - 25\% I 2 = 0% − 25% : Low / negligible heterogeneity.

I 2 = 25 % − 50 % I^2 = 25\% - 50\% I 2 = 25% − 50% : Mild to moderate heterogeneity.

I 2 = 50 % − 75 % I^2 = 50\% - 75\% I 2 = 50% − 75% : Substantial heterogeneity.

I 2 ≥ 75 % I^2 \ge 75\% I 2 ≥ 75% : High / considerable heterogeneity.

Managing High Heterogeneity : When I 2 I^2 I 2 is high ( > 50 % − 75 % >50\% - 75\% > 50% − 75% ), researchers should not blindly pool results. They must investigate the underlying biological causes using predefined subgroup analyses (e.g., separating term vs preterm infants, or oral vs intravenous administration) and meta-regression .

Funnel Plots and Publication Bias

Because trials reporting positive, statistically significant results are published more readily than negative or null studies, published literature suffers from publication bias . [Funnel Plot: Symmetrical] [Funnel Plot: Asymmetrical (Investigate)]

  • Standard Error Standard Error
  • (Precision) (Precision)
  • |
  • Low | * * Low | * * *
  • | * * * | * * *
  • | * * * | * * *
  • | * * * | * * *
  • | * * * | * * *
  • High |* * * High |* (EMPTY!)
  • +------------------------- +-------------------------
  • Treatment Effect Treatment Effect

Visual Funnel Plot : A scatter plot of treatment effect on the horizontal axis against a measure of study precision (standard error or sample size) on the vertical axis.

Symmetry : In the absence of bias, large studies with high precision cluster near the true effect at the top, while small studies with lower precision scatter widely at the base, creating a symmetrical inverted funnel.

Asymmetry : An asymmetric distribution suggests small-study effects. Publication bias is one explanation; heterogeneity, methodological differences and chance are others.

Statistical Testing : Appropriate asymmetry tests, such as Egger's regression , generally require at least 10 studies. A small p-value supports asymmetry, not a confirmed cause; choose a test suitable for the effect measure.

Health Economics and Decision Analysis in Paediatrics

Healthcare resources are finite. Health economic evaluations compare the costs and clinical consequences of alternative healthcare strategies to inform policy and resource allocation.

Typology of Economic Evaluations

Cost-Minimization Analysis (CMA) : Evaluates costs only; can only be applied when clinical outcomes of two competing interventions have been proven to be completely identical (e.g., comparing brand-name vs generic oral cephalexin).

Cost-Effectiveness Analysis (CEA) : Quantifies outcomes in natural, objective clinical units (e.g., cost per asthma hospitalisation prevented, cost per life-year gained).

Cost-Utility Analysis (CUA) : Quantifies health outcomes in standardized preference-based utility metrics, primarily Quality-Adjusted Life Years (QALYs) . This allows direct comparison across completely different medical disciplines (e.g., comparing paediatric cochlear implantation to neonatal surfactant replacement).

Cost-Benefit Analysis (CBA) : Measures both costs and outcomes strictly in monetary terms (e.g., euros spent vs euros saved). While theoretically versatile, it raises significant ethical objections when attempting to assign a monetary monetary value to a child's life.

Calculating QALYs and the Incremental Cost-Effectiveness Ratio (ICER)

Quality-Adjusted Life Year (QALY) : QALY = Health Utility Weight ( U ) × Time in that health state ( t ) \text{QALY} = \text{Health Utility Weight } (U) \times \text{Time in that health state } (t) QALY = Health Utility Weight ( U ) × Time in that health state ( t ) (Utility U = 1 U=1 U = 1 denotes full health and U = 0 U=0 U = 0 death; states valued worse than death can have negative utility) .

Incremental Cost-Effectiveness Ratio ( I C E R ICER I CER ) : I C E R = Cost New Intervention − Cost Standard Care Effect New Intervention − Effect Standard Care = Δ C Δ E ICER = \frac{\text{Cost}_{\text{New Intervention}} - \text{Cost}_{\text{Standard Care}}}{\text{Effect}_{\text{New Intervention}} - \text{Effect}_{\text{Standard Care}}} = \frac{\Delta C}{\Delta E} I CER = Effect New Intervention ​ − Effect Standard Care ​ Cost New Intervention ​ − Cost Standard Care ​ ​ = Δ E Δ C ​

Cost-Effectiveness Thresholds : For a more-effective, more-costly option, compare its ICER with the applicable willingness-to-pay threshold. Reject costlier, less-effective options; for other quadrants use incremental net benefit ( λ Δ E − Δ C \lambda\Delta E-\Delta C λ Δ E − Δ C ). Europe has no single threshold. From April 2026, NICE technology appraisals use a standard range of £25,000–£35,000 per QALY, with programme-specific rules and uncertainty considered.

Sensitivity Analysis : Tests the robustness of the economic model by systematically varying uncertain parameters (e.g., drug prices, complication rates) across plausible ranges (one-way, multi-way, or probabilistic Monte Carlo simulations).

Paediatric Research Ethics and Legal Regulatory Frameworks

Paediatric clinical research operates under rigorous ethical and legal doctrines established to protect children from exploitation while ensuring they are not denied the benefits of scientific progress. [Paediatric Research Ethics Framework]

  • |
  • +---------------------+---------------+---------------------+---------------------+
  • | | | | |
  • [Declaration of Helsinki] [GCP / EU Reg] [Parental Consent] [Child Assent] [Emergency Care]
  • Primacy of child's - EU 536/2014 - Mandatory proxy - Developmentally - Deferred consent
  • welfare over science - Paediatric legal permission tailored agreement - Narrow window
  • Independent IRB Plans (1901/2006) from guardians - Dissent respected! - Life-threatening
  • Historical Foundations and Guidelines

The Declaration of Helsinki (WMA) : Establishes that the health and welfare of the individual research participant must always take precedence over the interests of science and society.

ICH Good Clinical Practice (GCP E6) : The international quality standard for designing, conducting, and reporting clinical trials involving human subjects.

The "Therapeutic Orphan" Concept : Historically, protective regulations excluded children from drug trials. Consequently, medicines were prescribed off-label without paediatric safety or efficacy data. Modern ethical consensus dictates that children deserve evidence-based healthcare , making paediatric research an ethical necessity.

European Clinical Trials Regulation (Regulation EU No 536/2014) :

Requires scientific grounds for direct benefit outweighing risks/burdens, or benefit for the population represented by the minor with minimal risk and burden compared with standard treatment of the minor's condition . The trial must also meet Article 32's necessity, relevance and consent safeguards.

Paediatric Investigation Plans (PIPs) arise under the separate Paediatric Regulation (EC) No 1901/2006 . Applicable marketing-authorisation applications need an agreed plan with compliance, or a relevant waiver/deferral. A deferral can permit adult authorisation before the paediatric studies are completed.

Informed Consent, Child Assent, and Dissent

For clinical trials, minority means being below the national age of legal competence to give informed consent. Obtain the legally designated representative's permission and involve the child according to maturity and national assent requirements:

Parental Informed Consent (Informed Proxy Consent) :

Both parents or legal guardians (subject to national civil law requirements) must provide voluntary, written informed consent after being fully informed of potential risks, discomforts, benefits, and alternative therapies.

Consent can be withdrawn at any time without penalty or compromise to standard medical care.

Child Assent :

Assent is the affirmative, developmentally appropriate agreement of a child to participate in research. Assent is not merely the absence of an objection; it must be an active, informed choice.

Age-Appropriate Information : Information sheets must be written in child-friendly language with illustrations or multimedia tailored to the child's developmental maturity. [Developmental Participation and Consent]

  • Young children Representative consent; simple explanation and reassurance
  • School-age children Seek active assent using language/pictures suited to understanding
  • Adolescents Seek informed assent and document it as national rules require
  • Legal competence Obtain the participant's own informed consent to continue

There is no single EU age cutoff for written assent or independent trial consent.

The Primacy of Child Dissent :

A child capable of forming an opinion and assessing the information may explicitly refuse or withdraw; that wish must be respected , even with representative consent. Distress requires a pause and assessment of whether it expresses refusal, with pain and fear addressed.

EU medicinal-product trials : Article 32(1)(c) provides no life-saving-benefit exception to a capable minor's explicit refusal. Address distress and misunderstanding, but do not impose trial participation against that refusal; continue appropriate clinical care.

Research Involving Emergency and Critical Care Paediatric Patients

In acute paediatric emergencies (e.g., refractory status epilepticus, severe traumatic brain injury, septic shock, paediatric cardiac arrest), experimental therapies must be administered within a hyper-acute therapeutic window (often minutes), when parents are absent, traumatised, or incapable of informed decision-making.

Deferred Consent (Exception from Informed Consent) :

Permitted under EU Regulation No 536/2014 under strict statutory prerequisites:

A sudden life-threatening or other sudden serious condition prevents prior information and informed consent.

The therapeutic window makes prior representative information and consent impossible.

Scientific grounds support potential direct clinically relevant benefit for the participant.

The investigator knows of no previously expressed objection. The trial directly concerns the emergency condition and can only be conducted in emergencies.

Relative to standard treatment, risk and burden are minimal; the authorised protocol and ethics review explicitly cover emergency enrolment.

Seek representative consent for continued participation without undue delay , and involve the child as soon as possible. If consent is refused, explain the right to object to use of already-collected trial data.